Hepatocyte growth factor/scatter factor and prostate cancer: A review

Histology and Histopathology

Volumn 20, Issue 4, 2005, Pages 1339-1349

  Hurle, Rhidian A ^a   Davies, G ^a   Parr, C ^a   Mason, M D ^a   Jenkins, S A ^b   Kynaston, H G ^b   Jiang, W G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

c Met; Hepatocyte growth factor; Prostate cancer; Scatter factor

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

CANCER GROWTH; CANCER INVASION; HUMAN; MEDICAL RESEARCH; METASTASIS; MITOGENICITY; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW;

ANIMALS; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 27144451825     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Bardelli A., Longati P., Albero D., Goruppi S., Schneider C., Ponzetto C. and Comoglio P.M. (1996). HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. EMBO J. 15, 6205-6212.
2. Boccaccio C., Gaudino G., Gambarotta G., Galimi F. and Comoglio P.M. (1994). Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J. Biol. Chem. 269, 12846-12851.
3. Breslow N., Chan C.W., Dhom G., Drury R.A., Franks L.M., Gellei B., Lee Y.S., Lundberg S., Sparke B., Sternby N.H. and Tulinius H. (1977). Latent carcinoma of prostate at autopsy in seven areas. Int. J. Cancer 20, 680-688.
4. Brinkmann V., Foroutan H., Sach M., Weidner K.M. and Birchmeier W. (1995). HGF induces a variety of tissue-specific morphogenic programs in epithelial-cells. J. Cell Biol. 131, 1573-1586.
5. Bussolino F., Di Renzo M.F., Ziche M., Bocchietto E.. Olivero M., Naldini L., Gaudino G., Tamagnone L. Coffer A. and Comoglio P.M. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629-641.
6. Cancer Research UK; www.cancerresearchuk.org/aboutcancer/statistics/ incidence
7. Chen P., Xie H., Sekar M.C., Gupta K. and Wells A. (1994). Epidermal growth factor receptor-mediated cell motility: phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J. Cell Biol. 127, 847-857.
8. Cooper C.S., Park M., Blair D.G., Tainsky M.A., Huebner K., Croce C.M and Vande Woude G.F. (1984). Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29-33.
9. Crepaldi T., Pollack A.L., Prat M., Zborek A., Mostov K. and Comoglio P.M. (1994). Targeting of the HGF/SF receptor to the basolateral domain of polarized epithelial cells. J. Cell Biol. 125, 313-320.
10. Davies G., Jiang W.G. and Mason M.D. (2000). Cell-cell adhesion molecules and signalling intermediates and their role in the invasive potential of prostate cancer cells. J. Urol. 163, 985-992.
11. Davies G., Jiang W.G. and Mason M.D. (2001a). HGF/SF modifies the interaction between its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells. Int. J. Mol. Med. 7, 385-388.
12. Davies G., Jiang W.G. and Mason M.D. (2001b). Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin. Cancer Res. 7, 3289-3297.
13. Davies G., Mason M.D. and Martin T.A. (2003). The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumour growth and angiogenesis in vivo. Int. J. Cancer 106, 348-354
14. Davies G., Watkins G., Mason M. and Jiang W.G. (2004a). Targeting the HGF/SF receptor c-Met using the hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells. Prostate 60, 317-324
15. Davies G., Jiang W.G. and Mason M.D. (2004b). Hepatocyte Growth Factor/Scatter Factor and prostate cancer metastasis. Cancer Metatastasis - Biology and Treatment of Metastasis of Prostate Cancer. Kluwer Academic Publishers.
16. Dunsmore S.E., Rubin J.S., Kovacs So, Chedid M.. Parks W.C. and Welgus H.G. (1996). Mechanisms of Hepatocyte growth factor stimulation of keratinocyte metalloproteinase production. J. Biol. Chem. 271, 24567-24582.
17. Faletto D.L. (1993). In: HGF/SF and the c-Met receptor. Goldberg I.D. and Rosen E.M. (eds). Basel. Birkhauser. pp 107-130
18. Fan S., Ma Y.X., Wang J.A., Yuan R.Q., Meng Q., Cao, Y., Laterra J.J., Goldberg I.D. and Rosen E.M. (2000). The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signalling through phosphatidyl inositol 3′ kinase. Oncogene 19, 2212-2223.
19. Ferracini R., Longati P., Naldini L., Vigna E. and Comoglio P.M. (1991). Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J. Biol. Chem. 266, 19558-19564.
20. Fischer J., Palmedo G., von Knobloch R., Bugert P., Prayer-Galetti T., Pagano F. and Kovacs G. (1988). Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17, 733-739.
21. Fukuyama R., Ichijoh Y., Minoshima S., Kitamura N. and Shimizu N. (1991). Regional localization of the hepatocyte growth factor (HGF) gene to human chromosome 7 band q21.1. Genomics 11, 410-415.
22. Furlong R.A., Takehara T., Taylor W.G., Nakamura T. and Rubin J.S. (1991). Comparison of biological and immunochemical properties indicate that scatter factor and hepatocyte growth factor are indistinguishable. J. Cell Sci. 100, 173-177.
23. Gaudino G., Follenzi A., Naldini L, Collesi C. Santoro M., Gallo K.A., Godowski P.J. and Comoglio P.M. (1994). RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 13, 3524-3532.
24. Gherardi E and Stoker M. (1990). Hepatocytes and scatter factor. Nature 346, 228.
25. Giancotti F.G and Mainiero F. (1994). Integrin-mediated adhesion and signalling in tumourgenesis. Biochem. Biophys. Acta. 1198, 4-64.
26. Giordano S., Di Renzo M.F., Narsimhan R.P., Cooper C.S., Rosa C. and Comoglio P.M. (1989). Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene 4, 1383-1388.
27. Gmyrek G.A., Walburg M., Webb C.P., Yu H.M. You X. Vaughan E.D. Vande Woude G.F. and Knudsen B.S. (2001). Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am. J.Pathol. 159, 579-590.
28. Harrison G.M., Davies G., Martin T.A. Jiang W.G. and Mason M.D. (2002). Distribution and expression of CD44 isoforms and Ezrin during prostate cancer-endothelium interaction. J. Oncol. 21, 935-940.
29. Higashio K., Shima N., Goto M., Itagaki Y., Nagao M., Yasuda H. and Morinaga T. (1990). Identity of a tumor cytotoxic factor from human fibroblasts and hepatocyte growth factor. Biochem. Biophys. Res. Commun. 170, 397-404
30. Hiscox S. and Jiang W.G. (1998). HGF/SF regulates the phosphorylation of β-catenin and cell-cell adhesion in cancer cells. Proc. Am. Assoc. Cancer Res. 139, 500-501.
31. Huff J.L., Jelinek M.A., Borgman C.A., Lansing T.J. and Parsons J.T. (1993). The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/hepatocyte growth factor/scatter factor receptor. Proc. Natl. Acad. Sci. USA 90, 6140-6144.
32. Humphrey P.A., Zhu X., Zarnegar R., Swanson P.E. Ratliff T.L., Vollmer R.T. and Day M.L. (1995). Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147, 386-396.
33. Idini L X. and Humphrey P.A. (2000). Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 56, 1071-1074.
34. 2+. Exp. Cell Res. 220, 424-433.
35. Jiang W.G. and Hiscox S. (1997). Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol. Histopathol. 12, 537-555.
36. Jiang W.G., Bryce R.P., Horrobin D.F. and Mansel R.E. (1997). Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells. Prosta. Leuko. Essent. Fatty Acid 56, 307-316.
37. Jiang W., Hiscox S., Matsumoto K. and Nakamura T. (1999). Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit. Rev. Oncol.-Hematol. 29, 209-248.
38. Jiang W.G., Martin T.A., Parr C., Davies G., Matsumoto K. and Nakamura T. (2005). Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncology-Hematology. 253, 35-69.
39. Kawaguchi T., Qin L., Shimomura T., Kondo J., Matsumoto K., Denda K. and Kitamura N. (1997). Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J. Biol. Chem. 272, 27558-27564.
40. KawakamiKimura N., Narita T., Ohmori K., Yoneda T., Matsumoto K., Nakamura T. and Kannagi R. (1997). Involvement of HGF in increase integrin expression on HepG2 cells triggered by adhesion to endothelial cells. Br. J. Cancer 75, 47-53.
41. Knudsen B.S. Gmyrek G.A., Inra J., Scherr D.S. Vaughan E.D. Nanus D.M. Kattan M.W. Gerald W.L. and Vande Woude G.F. (2002). High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60, 1113-1117.
42. Koeneman K.S., Yeung F. and Chung L.W. (1999). Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39, 246-261.
43. Krill D., Shuman M., Thompson M.T., Becich M.J. and Strom S.C. (1997). A simple method for the isolation and culture of epithelial and stromal cells from benign and neoplastic prostates. Urology 49, 981-988.
44. Kurimoto S., Moriyama N., Horie S., Sakai M., Kameyama S., Akimoto Y., Hirano H. and Kawabe K. (1998). Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem. J. 27-32.
45. Laguda B., Selden C., Jones M., Hodgson H. and Spurr N.K. (1991). Assignment of the hepatocyte growth factor (HGF) to chromosome 7q22-qter. Ann. Human Genet. 55, 213-216.
46. Lang S.H., Clarke N.W., George N.J. and Testa N.G. (1999). Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. Clin. Exp. Metast. 17, 333-340.
47. Lin C.Y., Anders J., Johnson M., Sang Q.A. and Dickson R.B. (1999). Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem 274, 18231-18236.
48. Mars W.M., Kim T.H., Stolz D.B. Liu M.L and Michalopoulos G.K. (1996). Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Cancer Res. 56, 2837-2843.
49. Martin T.A. and Jiang W.G. (2001). Tight junctions and their role in cancer metastasis. Histol. Histopathol. 16, 1183-1195.
50. Matsumoto K., Takehara T., Inoue H., Hagiya M., Shimizu S. and Nakamura T. (1991). Deletion of kringle domains or the N-terminal hairpin structure in hepatocyte growth factor results in marked decreases in related biological activities. Biochem. Biophys. Res. Commun. 181, 691-699.
51. Matsumoto K., Tajima H., Okazaki H. and Nakamura T. (1993). Heparin as an inducer of hepatocyte growth factor. J. Biochem. 114, 820-826.
52. Matsumoto K., Tajima H., Okazaki H. and Nakamura T. (1992). Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J. Biol. Chem. 267, 24917-24920.
53. Matsumoto K. and Nakamura T. (1997). HGF: its organotrophic role and therapeutic potential. In: Plasminogen-related growth factors. Gherardi E. (ed). John Wiley & Sons. pp 198-214.
54. Michalopoulos G., Houck K,A., Dolan M.L. and Leutteke N.C. (1984). Control of hepatocyte replication by two serum factors. Cancer Res. 44, 4414-4419.
55. Miura H., Nishimura K., Tsujimura A., Matsumiya K.. Matsumoto K., Nakamura T. and Okuyama A. (2001). Effects of hepatocyte growth factor on E-cadherin-mediated cell-cell adhesion in DU145 prostate cancer cells. Urology 58, 1064-1069.
56. Miyazawa K., Shimomura T., Naka D. and Kitamura N. (1994). Proteolytic activation of hepatocyte growth factor in response to tissue injury. J. Biol. Chem. 269, 8966-8970.
57. Miyazawa K., Shimomura T. and Kitamura N. (1996). Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J. Biol. Chem. 271, 3615-3618
58. Mizuno K., Tanoue Y., Okano I., Harano T., Takada K. and Nakamura T. (1994). Purification and characterization of hepatocyte growth factor (HGF)-converting enzyme: activation of pro-HGF. Biochem. Biophysic. Res. Commun. 198, 1161-1169.
59. Moghul A., Lin L., Beedle A., Kanbour-Shakir A., DeFrances M.C. Liu Y. and Zarnegar R. (1994). Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 9, 2045-2052.
60. Montesano R., Matsumoto K., Nakamura T. and Orci L. (1991). Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 1991; 67, 901-908
61. Morimoto A., Tada K., Nakayama Y., Kohno K., Naito S., Ono M. and Kuwano M. (1994). Cooperative roles of hepatocyte growth factor and plasminogen activator in tubular morphogenesis by human microvascular endothelial cells. Jpn. J. Cancer Res. 85, 53-62.
62. Nakamura T., Nawa K. and Ichihara A. (1984). Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 122, 1450-1459.
63. Nakamura T., Nishizawa T., Hagiya M.. Seki T., Shimonishi M., Sugimura A., Tashiro K. and Shimizu S. (1989). Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440-443.
64. Nakashiro K., Okamoto M., Hayashi Y. and Oyasu R. (2000). Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells. Am. J. Pathol. 157, 795-803.
65. Naldini L, Tamagnone L and Vigna E. (1992). Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J.11, 4825-4833.
66. Naughton M., Picus J., Zhu X., Catalona W.J., Vollmer R.T. and Humphrey P.A. (2001). Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. Journal of Urology 165, 1325-8
67. Nishimura K., Kitamura M., Takada S., Nonomura N., Tsujimura A., Matsumiya K., Miki T., Matsumoto K. and Okuyama A. (1998). Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int. J. Urol. 5, 276-281.
68. Nishimura K., Kitamura M., Miura H., Nonomura N., Takada S., Takahara S., Matsumoto K., Nakamura T. and Matsumiya K. (1999). Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumour-stromal interaction. Prostate 41, 145-153
69. Office for National Statistics. (1999). Mortality statistics - cause, England and Wales. London: Stationery Office, 2000
70. Okajima A., Miyazawa K., Naitoh Y., Inoue K. and Kitamura N. (1997). Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation. Hepatology 25, 97-102.
71. Parr C. and Jiang W.G. (2001). Hepatocyte growth factor activators, inhibitors and antagonists and their implication in cancer intervention. Histol. Histopathol. 16, 251-268.
72. Parr C., Davies G., Nakamura T., Matsumoto K., Mason M.D. and Jiang W.G. (2001). The HGF/SF-induced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant. Bioche. Biophys. Res. Commun. 285, 1330-1337.
73. Pasdar M., Li Z., Marreli M., Nguyen B.T., Park M. and Wong K. (1997). Inhibition of junction assembly in cultured epithelial cells by hepatocyte growth factor/scatter factor is concomitant with increased stability and altered phosphorylation of the soluble junctional molecules. Cell Growth Differ. 8, 451-462.
74. Pisters L.L., Troncoso P., Zhau H.E., Li W., von Eschenbach A.C. and Chung L.W. (1995). c-Met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 154, 293-298.
75. Ponzetto C., Bardelli A., Zhen Z., Maina F., dalla Zonca P., Giordano S., Graziani A., Panayotou G. and Comoglio P.M. (1994). A multifunctional docking site mediates signalling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271.
76. Presnell S.C., Borchert K., Gregory C., Maygarden S., Smith G. and Mohler J. (2001). Differential expression of hepatocyte growth factor and c-met in prostate cancer amongst Caucasian American vs. African American. FASEB J. 15, A239-239.
77. Qadan L.R., Perez-Stable C.M., Schwall R.H., Burnstein K.L., Ostenson R.C. Howard G.A. and Roos B.A. (2000). Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines. Endocrinology 141, 2567-2573.
78. Ronsin C., Muscatelli F., Mattei M.G. and Breathnach R. (1993). A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8, 1195-1202.
79. Rosen E.M., Grant D., Kleinman H., Jaken S., Donovan M.A., Setter E., Luckett P.M., Carley W., Bhargava M. and Goldberg I.D. (1991). Scatter factor stimulates migration of vascular endothelium and capillary-like tube formation. EXS 59, 76-88.
80. Russell W.E., McGowan J.A. and Bucher N.L. (1984). Partial characterization of a hepatocyte growth factor from rat platelets. J. Cell. Physiol. 119, 183-192.
81. Shiraishi T., Watanabe M., Matsuura H., Kusano I., Yatani R. and Stemmermann G.N. (1994). The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo 8, 445-447.
82. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E. and Mack T.M. (1991). Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 63, 963-966.
83. Shimomura T., Miyazawa K., Komiyama Y., Hiraoka H. Naka D., Morimoto Y. and Kitamura N. (1995). Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur. J. Biochem. 229, 257-261.
84. Shimomura T., Denda K., Kitamura A., Kawaguchi T., Kito M., Kondo J., Kagaya S., Qin L., Takata H., Miyazawa K. and Kitamura N. (1997). Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem. 272, 6370-6376.
85. Stoker M. and Perryman M. (1985). An epithelial scatter factor released by embryo fibroblasts. J. Cell Sci. 77, 209-223.
86. Tsuka H., Mori H., Li B., Kanamaru H., Matsukawa S. and Okada K. (1998). Enhanced hepatocyte growth factor level in human prostate cancer treated with endocrine therapy. Int. J. Oncol. 13, 169-176.
87. Tsuka H., Mori H., Li B., Kanamaru H., Matsukawa S. and Okada K. (1998). Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues. Int. J. Oncol. 13, 927-934.
88. You X., Yu H,M., Cohen-Gould L,, Cao B., Symons M., Vande Woude G.F. and Knudsen B.S. (2003). Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. Exp. Cell Res. 288, 246-256.
89. Watanabe M., Fukutome K., Kato H., Murata M. Kawamura J., Shiraishi T. and Yatani R. (1999). Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett. 141, 173-178.
90. Weidner K.M., Behrens J., Vandekerckhove J. and Birchmeier W. (1990). Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 11, 2097-2108.
91. Weimar I.S., de Jong D., Muller E.J., Nakamura T., van Gorp J,M., de Gast G.C. and Gerritsen W.R. (1997). Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 89, 990-1000.
92. Weimar I.S., Miranda N., Muller E.J., Hekman A., Kerst J.M., de Gast G.C. and Gerritsen W.R. (1998). Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Exp. Hematol. 26, 885-894.
93. Zarnegar R., Muga S., Enghild J. and Michalopoulos G. (1989). NH2-terminal amino acid sequence of rabbit hepatopoietin A, a heparin-binding polypeptide growth factor for hepatocytes. Biochem. Biophys. Res. Commun. 163, 1370-1376.
94. Zarnegar R. and Michalopoulos G.K. (1995). The many faces of Hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J. Cell Biol. 129, 1170-1180.
95. Zhu X. and Humphrey P.A. (2000). Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 56, 1071-1074.